Malignant Pleural Mesothelioma: an Update for Pulmonologists

Calvinjit Sidhu, Amber Louw, Fraser Brims, Jenette Creaney, Y. C. Gary Lee

Research output: Contribution to journalArticle

Abstract

Purpose of ReviewMalignant pleural mesothelioma (MPM) is an incurable disease, and its global incidence is predicted to rise. The epidemiology is changing especially in developed countries where the increases in incidence centers around the older age group. Pulmonologists are the frontline specialists faced with the challenges of diagnosing MPM and management of the associated respiratory issues, especially malignant pleural effusions. Although much of recent literature surrounds treatment of MPM, this review highlights latest developments in aspects of MPM care relevant to pulmonologists' practice.Recent FindingsAdvances in imaging have allowed more MPM cases to be diagnosed with percutaneous-guided biopsy without resorting to thoracoscopy. Cytological examination, coupled with molecular testing (e.g., BAP-1 loss and fluorescent in situ hybridization for CDKN2A gene loss), now allows many cases of MPM to be diagnosed by pleural fluid cytology. Many biomarkers have been proposed for mesothelioma; however, work is needed to first validate initial studies and then tease-out the interactions between known prognostic indicators and any proposed biomarker. A series of multicenter randomized trials have established the role of indwelling pleural catheter (IPC) as the choice of management for malignant pleural effusions. Combining IPC with talc pleurodesis is a new approach. Prognostic factors, including a new algorithm, are reviewed to assist pulmonologists.SummaryMany guidelines have been published by various agencies, again with different recommendations (especially regarding therapies). Pulmonologists must therefore stay abreast of the literature in order to provide the best care for patients.

Original languageEnglish
Pages (from-to)40-49
Number of pages10
JournalCurrent Pulmonology Reports
Volume8
Issue number2
DOIs
Publication statusPublished - Jun 2019

Cite this

Sidhu, Calvinjit ; Louw, Amber ; Brims, Fraser ; Creaney, Jenette ; Lee, Y. C. Gary. / Malignant Pleural Mesothelioma : an Update for Pulmonologists. In: Current Pulmonology Reports. 2019 ; Vol. 8, No. 2. pp. 40-49.
@article{5094e9cf19c347389be2e1b368cb170f,
title = "Malignant Pleural Mesothelioma: an Update for Pulmonologists",
abstract = "Purpose of ReviewMalignant pleural mesothelioma (MPM) is an incurable disease, and its global incidence is predicted to rise. The epidemiology is changing especially in developed countries where the increases in incidence centers around the older age group. Pulmonologists are the frontline specialists faced with the challenges of diagnosing MPM and management of the associated respiratory issues, especially malignant pleural effusions. Although much of recent literature surrounds treatment of MPM, this review highlights latest developments in aspects of MPM care relevant to pulmonologists' practice.Recent FindingsAdvances in imaging have allowed more MPM cases to be diagnosed with percutaneous-guided biopsy without resorting to thoracoscopy. Cytological examination, coupled with molecular testing (e.g., BAP-1 loss and fluorescent in situ hybridization for CDKN2A gene loss), now allows many cases of MPM to be diagnosed by pleural fluid cytology. Many biomarkers have been proposed for mesothelioma; however, work is needed to first validate initial studies and then tease-out the interactions between known prognostic indicators and any proposed biomarker. A series of multicenter randomized trials have established the role of indwelling pleural catheter (IPC) as the choice of management for malignant pleural effusions. Combining IPC with talc pleurodesis is a new approach. Prognostic factors, including a new algorithm, are reviewed to assist pulmonologists.SummaryMany guidelines have been published by various agencies, again with different recommendations (especially regarding therapies). Pulmonologists must therefore stay abreast of the literature in order to provide the best care for patients.",
keywords = "Mesothelioma, Pleural effusion, Indwelling pleural catheter, Biomarker, Prognosis, PROGNOSTIC-FACTORS, SERUM MESOTHELIN, BRCA1-ASSOCIATED PROTEIN-1, BAP1 IMMUNOHISTOCHEMISTRY, PROPHYLACTIC RADIOTHERAPY, TALC PLEURODESIS, ASBESTOS USE, CHEST TUBE, DIAGNOSIS, EFFUSION",
author = "Calvinjit Sidhu and Amber Louw and Fraser Brims and Jenette Creaney and Lee, {Y. C. Gary}",
year = "2019",
month = "6",
doi = "10.1007/s13665-019-0224-9",
language = "English",
volume = "8",
pages = "40--49",
journal = "Current Pulmonology Reports",
issn = "2199-2428",
publisher = "Springer",
number = "2",

}

Malignant Pleural Mesothelioma : an Update for Pulmonologists. / Sidhu, Calvinjit; Louw, Amber; Brims, Fraser; Creaney, Jenette; Lee, Y. C. Gary.

In: Current Pulmonology Reports, Vol. 8, No. 2, 06.2019, p. 40-49.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Malignant Pleural Mesothelioma

T2 - an Update for Pulmonologists

AU - Sidhu, Calvinjit

AU - Louw, Amber

AU - Brims, Fraser

AU - Creaney, Jenette

AU - Lee, Y. C. Gary

PY - 2019/6

Y1 - 2019/6

N2 - Purpose of ReviewMalignant pleural mesothelioma (MPM) is an incurable disease, and its global incidence is predicted to rise. The epidemiology is changing especially in developed countries where the increases in incidence centers around the older age group. Pulmonologists are the frontline specialists faced with the challenges of diagnosing MPM and management of the associated respiratory issues, especially malignant pleural effusions. Although much of recent literature surrounds treatment of MPM, this review highlights latest developments in aspects of MPM care relevant to pulmonologists' practice.Recent FindingsAdvances in imaging have allowed more MPM cases to be diagnosed with percutaneous-guided biopsy without resorting to thoracoscopy. Cytological examination, coupled with molecular testing (e.g., BAP-1 loss and fluorescent in situ hybridization for CDKN2A gene loss), now allows many cases of MPM to be diagnosed by pleural fluid cytology. Many biomarkers have been proposed for mesothelioma; however, work is needed to first validate initial studies and then tease-out the interactions between known prognostic indicators and any proposed biomarker. A series of multicenter randomized trials have established the role of indwelling pleural catheter (IPC) as the choice of management for malignant pleural effusions. Combining IPC with talc pleurodesis is a new approach. Prognostic factors, including a new algorithm, are reviewed to assist pulmonologists.SummaryMany guidelines have been published by various agencies, again with different recommendations (especially regarding therapies). Pulmonologists must therefore stay abreast of the literature in order to provide the best care for patients.

AB - Purpose of ReviewMalignant pleural mesothelioma (MPM) is an incurable disease, and its global incidence is predicted to rise. The epidemiology is changing especially in developed countries where the increases in incidence centers around the older age group. Pulmonologists are the frontline specialists faced with the challenges of diagnosing MPM and management of the associated respiratory issues, especially malignant pleural effusions. Although much of recent literature surrounds treatment of MPM, this review highlights latest developments in aspects of MPM care relevant to pulmonologists' practice.Recent FindingsAdvances in imaging have allowed more MPM cases to be diagnosed with percutaneous-guided biopsy without resorting to thoracoscopy. Cytological examination, coupled with molecular testing (e.g., BAP-1 loss and fluorescent in situ hybridization for CDKN2A gene loss), now allows many cases of MPM to be diagnosed by pleural fluid cytology. Many biomarkers have been proposed for mesothelioma; however, work is needed to first validate initial studies and then tease-out the interactions between known prognostic indicators and any proposed biomarker. A series of multicenter randomized trials have established the role of indwelling pleural catheter (IPC) as the choice of management for malignant pleural effusions. Combining IPC with talc pleurodesis is a new approach. Prognostic factors, including a new algorithm, are reviewed to assist pulmonologists.SummaryMany guidelines have been published by various agencies, again with different recommendations (especially regarding therapies). Pulmonologists must therefore stay abreast of the literature in order to provide the best care for patients.

KW - Mesothelioma

KW - Pleural effusion

KW - Indwelling pleural catheter

KW - Biomarker

KW - Prognosis

KW - PROGNOSTIC-FACTORS

KW - SERUM MESOTHELIN

KW - BRCA1-ASSOCIATED PROTEIN-1

KW - BAP1 IMMUNOHISTOCHEMISTRY

KW - PROPHYLACTIC RADIOTHERAPY

KW - TALC PLEURODESIS

KW - ASBESTOS USE

KW - CHEST TUBE

KW - DIAGNOSIS

KW - EFFUSION

U2 - 10.1007/s13665-019-0224-9

DO - 10.1007/s13665-019-0224-9

M3 - Article

VL - 8

SP - 40

EP - 49

JO - Current Pulmonology Reports

JF - Current Pulmonology Reports

SN - 2199-2428

IS - 2

ER -